Tissue Products and Kits From Renal Disease

肾病组织产品和试剂盒

• 批准号: 7154284
• 负责人: VERONIQUE L BARNES
• 金额: $ 38.96万
• 依托单位: PROBETEX, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-03-01 至 2008-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7154284
• 关键词: CD antigens; RNase protection assay; antibody; autoantigens; basement membrane; chronic renal failure; disease /disorder model; electron microscopy; glomerulonephritis; immunocytochemistry; in situ hybridization; interstitial nephritis; laboratory rat; membranous glomerulonephritis; renal glomerulus; technology /technique development; tissue resource /registry

DESCRIPTION (provided by applicant): Kidney failure due to end-stage renal disease is escalating at an alarming rate, motivating renal investigators and clinicians to identify research priorities in search for better ways to prevent and treat kidney disease. There is a crucial need for increases in resources and manpower in research in kidney disease. An impediment to renal research has been dwindling resources and loss of protected time to devote to research in the face of an ever-increasing demand for further exploration of research ideas. There is a significant need and market potential for readily available reagents and tissue products from established models and human cases of renal disease. To address this deficit, Probetex was founded as a "Renal Research Resource Company" to create a repository of "off-the-shelf" tissue products to provide readily available samples and help investigators to quickly and efficiently explore their ideas on established and standardized models or identified cases of human disease. This Phase II application focuses on large-scale production of reagents and tissue products (tissue sections, protein lysates, purified RNA, and prefabricated Western and Northern blots) derived from the six models of kidney disease collectively representing the most common forms of renal disease presented clinically. These same products will be developed from normal and diseased human kidney. The models include 1. Mesangial Proliferative Glomeruonephritis (anti-Thy-1), 2. Immune-mediated Crescentic Glomerulonephritis and Interstitial Nephritis (anti-GBM), 3. Membranous Nephropathy (anti-Fx1A), 4. Lupus nephritis, 5. Type 1 and 6. Type 2 diabetic nephropathy. This grant will enable large-scale processing of existing lots of sheep antibodies developed to create reagents to induce three classical immune models of kidney disease (1-3 above). Also, manufacture of tissue products from the disease models will be processed for distribution as single units or in multiple arrays of tissue and prefabricated Western and Northern blots for comparison analysis of samples of different diseases or time points in the same application. Also, as part of Probetex's mission, the company, will prepare for commercialization seven kidney cell lines (embryonic stem cells and glomerular mesangial, epithelial, and endothelial cells). A plan to expand the scope of products through licensing and out-sourcing strategies will be implemented as part of the company's long-range goal. One of the main obstacles facing physician- and basic scientists today is dwindling resources and loss of protected time to devote to their research in the face of an ever increasing demand for further exploration of research ideas in kidney disease. Readily available samples derived from experimental models and clinical cases of renal disease are not commercially available. Probetex, Inc. was founded as a "Renal Research Resource Company" and addresses the above research priorities by fostering research in kidney function and pathology by means of providing reagents, products, and services for the investigation of experimental and clinical renal disease. Probetex's products will enable investigator-customers to quickly and efficiently explore their research ideas on established and standardized models and identified cases of human renal disease increasing awareness, resources and further research in kidney disease.

描述（由申请人提供）：终末期肾脏疾病导致的肾衰竭正在以惊人的速度升级，促使肾脏研究人员和临床医生确定研究重点，以寻找更好的方法来预防和治疗肾脏疾病。肾脏疾病研究迫切需要增加资源和人力。肾脏研究的一个障碍是，面对不断增长的进一步探索研究思路的需求，资源不断减少，研究时间受到保护。对于来自已建立的肾脏疾病模型和人类病例的现成试剂和组织产品，存在显著的需求和市场潜力。为了解决这一问题，Probetex成立了一家“肾脏研究资源公司”，创建了一个“现成”组织产品的储存库，以提供现成的样本，并帮助研究人员快速有效地探索他们对已建立和标准化模型或已确定的人类疾病病例的想法。该II期申请侧重于大规模生产试剂和组织产品（组织切片、蛋白裂解物、纯化RNA和预制Western和北方印迹），这些试剂和组织产品来源于6种肾脏疾病模型，这些模型共同代表了临床上最常见的肾脏疾病形式。这些相同的产品将从正常和患病的人肾脏中开发。模型包括1.系膜增生性肾小球肾炎（抗Thy-1），2.免疫介导的新月体肾小球肾炎和间质性肾炎（抗GBM），3.膜性肾病（抗Fx1A），4.狼疮性肾炎5. 1型和6型。2型糖尿病肾病这笔赠款将使现有大量绵羊抗体的大规模加工成为可能，这些抗体被开发用于制造试剂，以诱导三种经典的肾脏疾病免疫模型（上文1 - 3）。此外，将对来自疾病模型的组织产品的制造进行处理，以作为单个单元或在多个组织阵列中分配，并预制Western和北方印迹，用于在相同应用中对不同疾病或时间点的样品进行比较分析。此外，作为Probetex使命的一部分，该公司将准备商业化七个肾细胞系（胚胎干细胞和肾小球系膜细胞、上皮细胞和内皮细胞）。作为公司长期目标的一部分，将实施通过许可和外包战略扩大产品范围的计划。当今医生和基础科学家面临的主要障碍之一是，面对不断增长的进一步探索肾脏疾病研究思路的需求，他们投入研究的资源不断减少，时间受到保护。从肾脏疾病的实验模型和临床病例中获得的现成样本尚未上市。Probetex公司作为一家"肾脏研究资源公司"成立，通过提供用于实验和临床肾脏疾病研究的试剂、产品和服务，促进肾功能和病理学研究，解决上述研究重点。Probetex的产品将使制药商客户能够快速有效地探索他们在已建立和标准化模型上的研究思路，并确定人类肾脏疾病病例，从而提高人们对肾脏疾病的认识、资源和进一步研究。